What Pharma Manufacturers Need to Know about the Inflation Reduction Act
Â
On August 16, 2022, President Biden signed the Inflation Reduction Act (IRA) into law (P.L. 117-169). The IRA is a comprehensive law that includes multiple provisions to provide financial relief for Medicare beneficiaries, improve access to care, while working to reduce overall drug expenditures by the federal government.
Â
Herspiegel has been working with clients to help understand the impacts, stay up to date as new guidance is released by the Centers for Medicare & Medicaid Services (CMS) and prepare for the effective dates of the key provisions. The IRA will make many new improvements to the Medicare program overall, bringing innovative, life-saving treatments to patients. Many on the pharmaceutical manufacturing side are focused on preparing for the Medicare Drug Price Negotiation Program (or ‘Negotiation Program’), while that potentially has the largest impact, there are other key provisions to be aware of.
We will continue to study these new provisions and the impacts as they evolve. We are committed to sharing that information with you. Sign up below to stay up to date as we release new articles and whitepapers.
GET THE LATEST UPDATES ON IRA POLICIES AND GUIDANCE
Updates on new provisions, policies, guidance, and impacts of the IRA.
"*" indicates required fields
Emily Phillips
Principal, Market Access
Herspiegel
Emily has 20+ years of reimbursement and market access experience, including providing multiple pharmaceutical and biotech clients with pre- and-post commercialization strategies and tactics to help launch a variety of physician-administered drugs, biologics, and devices. Emily worked with leaders across managed markets, reimbursement, trade, marketing, and sales teams to help overcome payer access barriers, including coverage, coding, and payment needs.